COMP and Salla disease: Afterwards, based on our phase II clinical studies ongoing (term_id, TRUCE-01; registration number, NCT04730219), we identified that the expression level of CLIC3/COMP/FASN/SCD/SLC1A6/ZNF600 in BCa groups with CR/PR response to tislelizumab combined with low-dose nab-paclitaxel therapy significantly decreased after treatment, whereas the expression level of CPNE8/CYTL1/DMRTA1/FOXC2 were upregulated after treatment in SD/PD non-responsive cases.